A Cost-Effectiveness Analysis of Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer

BACKGROUND: Currently, approved first-line treatment options of metastatic hormone-sensitive prostate cancer (mHSPC) include (1) androgen deprivation therapy (ADT) alone, ADT plus one of the following: (2) docetaxel, (3) abiraterone, (4) enzalutamide, and (5) apalutamide. The high cost of novel andr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sung, Winnie W. Y., Choi, Horace C. W., Luk, Peter H. Y., So, Tsz Him
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943717/
https://www.ncbi.nlm.nih.gov/pubmed/33718198
http://dx.doi.org/10.3389/fonc.2021.627083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943717/
https://www.ncbi.nlm.nih.gov/pubmed/33718198
http://dx.doi.org/10.3389/fonc.2021.627083

Ejemplares similares